Burning Rock Biotech (NASDAQ:BNR) Announces Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) posted its quarterly earnings data on Tuesday. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.29) by $2.09, Zacks reports. The company had revenue of $15.66 million for the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Burning Rock Biotech Price Performance

NASDAQ BNR opened at $8.83 on Friday. The firm’s 50 day moving average is $15.59 and its 200-day moving average is $21.20. The company has a quick ratio of 2.79, a current ratio of 3.05 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $92.89 million, a PE ratio of -10.77 and a beta of 1.32. Burning Rock Biotech has a 12-month low of $3.05 and a 12-month high of $41.72.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Burning Rock Biotech has an average rating of “Sell”.

Insider Activity

In related news, Director Yusheng Han acquired 314,870 shares of the firm’s stock in a transaction on Tuesday, March 31st. The shares were purchased at an average cost of $17.36 per share, for a total transaction of $5,466,143.20. Following the completion of the acquisition, the director directly owned 17,672,676 shares in the company, valued at approximately $306,797,655.36. This trade represents a 1.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 30.30% of the company’s stock.

Institutional Investors Weigh In On Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Marshall Wace LLP purchased a new position in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned 0.10% of Burning Rock Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.